We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Allarity Therapeutics Inc (ALLR) USD0.0001

Sell:$1.40 Buy:$1.42 Change: $0.17 (13.60%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Sell:$1.40
Buy:$1.42
Change: $0.17 (13.60%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Sell:$1.40
Buy:$1.42
Change: $0.17 (13.60%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allarity Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. It uses its DRP companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by its DRP companion diagnostics platform. Its lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptor (VEGFR). Its second priority therapeutic candidate, stenoparib, is a selective inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). Its third priority therapeutic candidate is IXEMPRA (ixabepilone).

Contact details

Address:
210 Broadway, Suite 201
CAMBRIDGE
02139
United States
Telephone:
+1 (401) 4264664
Website:
https://allarity.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALLR
ISIN:
US0167441049
Market cap:
$11.05 million
Shares in issue:
8.08 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Steve Carchedi
    Chief Executive Officer, Director
  • Jens Knudsen
    Chief Financial Officer
  • James Cullem
    Senior Vice President - Corporate Development
  • Thomas Jensen
    Senior Vice President - Information Technology
  • Steen Knudsen
    Chief Scientific Officer
  • Marie Foegh
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.